The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Primary results of the ICONIC phase 2 trial of perioperative FLOT plus avelumab (FLOT-A) in operable oesophagogastric adenocarcinoma (OGA).
 
Anderley Gordon
No Relationships to Disclose
 
Benjamin Challoner
No Relationships to Disclose
 
Avani Athauda
No Relationships to Disclose
 
Andrew Woolston
No Relationships to Disclose
 
Sonia Mansukhani
No Relationships to Disclose
 
Matt Dunstan
No Relationships to Disclose
 
Nikoletta Petrou
No Relationships to Disclose
 
Komel Khabra
No Relationships to Disclose
 
Retchel Lazaro-Alcausi
No Relationships to Disclose
 
Richard Crux
No Relationships to Disclose
 
Victoria Borja
No Relationships to Disclose
 
Ruwaida Begum
No Relationships to Disclose
 
Isma Rana
No Relationships to Disclose
 
Sheela Rao
Consulting or Advisory Role - AstraZeneca; Bayer; BeiGene; Hookipa Biotech; Merck
Speakers' Bureau - Merck; Merck Serono
Expert Testimony - Boehringer Ingelheim
Travel, Accommodations, Expenses - SERVIER
 
Sacheen Kumar
Speakers' Bureau - MSD
 
David Cunningham
Stock and Other Ownership Interests - OVIBIO
Consulting or Advisory Role - OVIBIO
Research Funding - 4SC (Inst); Bayer (Inst); Celgene (Inst); Clovis Oncology (Inst); Leap Oncology (Inst); Lilly (Inst); MedImmune (Inst); Roche (Inst)
 
Ian Chau
Honoraria - Eisai; Lilly; Roche/Genentech; SERVIER
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Eisai; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD Oncology; OncXerna Therapeutics; Roche/Genentech; Seagen; SERVIER; Sotio; Taiho Oncology; Turning Point Therapeutics
Research Funding - Janssen-Cilag (Inst); Lilly (Inst)
 
Naureen Starling
Honoraria - Amgen; GlaxoSmithKline; GlaxoSmithKline; Lilly; Lilly; Merck Serono; MSD Oncology; MSD Oncology; MSD Oncology; Novartis; Pierre Fabre; Pierre Fabre; Pierre Fabre; Seagen; SERVIER; SERVIER; SERVIER
Consulting or Advisory Role - AstraZeneca; MSD; MSD Oncology; Novartis Pharmaceuticals UK Ltd.; Pfizer
Research Funding - AstraZeneca (Inst); BMS (Inst); Pfizer/EMD Serono (Inst)
Travel, Accommodations, Expenses - Guardant Health; MSD Oncology
(OPTIONAL) Uncompensated Relationships - Guardant Health
 
M. Asif Chaudry
No Relationships to Disclose
 
Marco Gerlinger
Stock and Other Ownership Interests - Vertex
Research Funding - Bristol myers squibb; Merck; Roche/Genentech